联系我们

论文查询结果	返回搜索

论文编号：	10814
作者编号：	2120162798
上传时间：	2018/12/12 10:17:25
中文题目：	康哲药业许可战略研究
英文题目：	Research on the licensing strategy of China Medical System Holdings Limited
指导老师：	胡望斌
中文关键字：	许可战略；康哲药业；经营战略；战略分析
英文关键字：	Licensing strategy；China Medical System Holdings；Operation Strategy；Strategy analysis；
中文摘要：	制药公司拥有创新药、专利药等重磅产品是支撑公司销售额及公司发展的重要因素。但近几十年来，随着研发成本的增加，监管障碍的加强，以及制药行业商业竞争的加剧，参与新药开发的知识和技术复杂性的增加，公司对外部资源整合到自己的创新经验的需求日益增加。毫无疑问，制药公司将继续使用常用的方式，如许可交易、战略合作、兼并等方法资源外取。其中许可交易是较传统的方式，对于初创期公司和较快发展中的公司有更好的操作性。 中国的许可交易在全球的许可交易中所占的比例仅为4.3%，中国制药公司主要以研究和开发、生产、销售仿制药为主，整个行业对发达国家地区发生的许可交易背景，内涵及发展趋势了解不深。 制药公司应该也可以使许可交易作为公司竞争战略中不可或缺的一部分，但许可战略能够丰富制药公司，以及其他行业公司战略观点的相关文章很少。其中对外许可可以显著提高公司收入和促成战略联盟等方式支持战略目标，引入许可可以通过有效的商业化，获取技术和专利等方式支持战略目标。许可战略可以作为职能战略支持公司层战略和经营战略。 本课题主要研究在国内上市医药公司中通过“许可战略”发展的康哲药业。通过了解康哲药业的公司概况，分析所处的外部环境和内部环境，讨论其经营战略的选择。之后重点讨论康哲药业的许可战略的目标，许可战略的环境分析，并探讨许可战略与公司层战略、经营层战略、其他职能战略的关系，许可战略实施的要素。最后举例一个引入许可交易项目，通过折现现金法对许可交易项目的价值做评估，另从四个维度分析此交易项目对康哲药业产生的影响。
英文摘要：	Pharmaceutical companies have innovative drugs, patented drugs and other bluster product is key factor to the company's sales and R&D. But in recent decades, with the increase of R&D costs, regulatory barriers, and the intensification of business competition in the pharmaceutical industry, the complexity of knowledge and technology involved in new drug development has increased, and the need for enterprises to integrate external resources into their own innovative experience has increased. Undoubtedly, pharmaceutical companies will continue to use common methods such as licensing deals, strategic cooperation, mergers and acquisitions to extract resources. Licensing deal is a more traditional, but operational way for start-ups and fast-growing companies. China's licensing deals account for only 4.3% of the global licensing deals. Chinese pharmaceutical companies mainly produce and sell generic drugs. The whole industry has little understanding of the background, connotation and development trend of licensing deals happened in developed countries. Pharmaceutical companies should or be able to make licensing deal as an integral part of their strategies, but few articles have been written about licensing strategy that could enrich the strategy of pharmaceutical companies or other industry companies. Out-licensing can significantly increase corporate income and promote strategic alliances to support strategic objectives. The In-licensing can lead effective commercialization, acquisition of technology and patents to support strategic objectives. This study focuses on the development of public company，China Medical System Holdings Limited（“CMS”）through the "licensing strategy" in China. It discussed the choice of strategy through understanding the general situation of CMS, analyzing the external environment and internal environment. Then, it mainly studied on the target of licensing strategy, the analysis of licensing environment, the relationship between strategy and corporate strategy, management strategy, and the elements of licensing strategy implementation. Finally, an example is given to evaluate the value of one licensed transaction item by discounted cash flow method, and study the impact of this transaction item on CMS based on Balanced Score Card.
查看全文：	预览  下载(下载需要进行登录)